TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05229770

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fruit smoothie
Description: Participants randomised to the intervention arm will receive a 250 ml fruit smoothie as diet supplement for 20 weeks in addition to the regular OAT clinic follow-up. The fruit smoothies will be marketed products including combinations of the following fruits: apple, pineapple, mango, bananas, orange, blueberries, passion fruit, coconut, lime, and blackcurrant. The participants will receive a mixture of different smoothie types with the option of removing alternatives based on preferences. Fruit smoothie products will come in plastic bottles and will be delivered directly to the participants on a weekly basis. Each participant will receive a total of seven smoothie bottles per week with an oral agreement with each participant to consume one of these per day. Delivery of fruit smoothie will generally be given in parallel with delivery of OAT medication.
Study: NCT05188625

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telesupport - Telehealth
Description: Online self-paced dietary education videos; Dietary counselling via video consultation; Blood glucose monitoring via a specially-designed health app
Study: NCT06059157

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Advanced MRI
Description: resting-state functional MRI, diffusion with advanced post-processing (microstructure analysis), myelin mapping
Study: NCT06255717

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Comprehensive rehabilitation training
Description: Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~Pulmonary function training, including standing training, cough training, and diaphragm muscle training.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Comprehensive rehabilitation training
Description: Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~Pulmonary function training, including standing training, cough training, and diaphragm muscle training.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rise-bed Training
Description: gradually elevating the bed (head-up tilt) is one of the common methods to treat orthostatic hypotension. This treatment adjusts the patient's bed angle to gradually raise their body, promoting balanced blood distribution throughout the body and reducing orthostatic hypotension symptoms.~In head-up tilt treatment, the bed angle is usually gradually increased from a horizontal position, and the specific angle can be determined based on the patient's condition and tolerance. This treatment process is generally monitored and controlled by medical personnel to ensure safety and effectiveness.~The mechanism of head-up tilt treatment is to increase venous return by changing the body position and increasing the effect of gravity, thereby increasing cardiac preload, output, and blood pressure. This helps to reduce orthostatic hypotension symptoms such as dizziness, lightheadedness, and fatigue.
Study: NCT06037239

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linperlisib in combined with Chidamide
Description: Phase 1: dose escalation phase. Drug Linperlisib: 3 dose level of 40mg, 60mg, 80mg qd; Drug Chidamide: fixed dose of 20mg twice weekly.~Phase 2：dose expansion phase. Drug Linperlisib: RP2D established in the phase I study; Drug Chidamide: fixed dose of 20mg twice weekly in a 4-week cycle
Study: NCT05155449

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotics
Description: Capsule

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule
Study: NCT05083676

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceset Intervention
Description: . The intervention comprises of: i) Digital peer support training for youth befrienders to equip them with the knowledge and application of the four active ingredients-Mattering, selfhood, compassion, and mindfulness-to provide effective peer support as they respond to youth seekers' emotional experiences.~ii) Acceset Intervention with features or digital markers of psychological well-being, peer emotional disclosure process and community engagement.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Acceset Intervention
Description: . The intervention comprises of: i) Digital peer support training for youth befrienders to equip them with the knowledge and application of the four active ingredients-Mattering, selfhood, compassion, and mindfulness-to provide effective peer support as they respond to youth seekers' emotional experiences.~ii) Acceset Intervention with features or digital markers of psychological well-being, peer emotional disclosure process and community engagement.
Study: NCT04420819

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Ischemic Preconditioning
Description: The IPC is characterized by the application of brief periods of circulatory occlusion (ischemia) and reperfusion of a limb in the minutes to hours that precede the exercise through the insufflations and deflations of a pressure cuff

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ischemic Preconditioning
Description: The IPC is characterized by the application of brief periods of circulatory occlusion (ischemia) and reperfusion of a limb in the minutes to hours that precede the exercise through the insufflations and deflations of a pressure cuff

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ischemic Preconditioning
Description: The IPC is characterized by the application of brief periods of circulatory occlusion (ischemia) and reperfusion of a limb in the minutes to hours that precede the exercise through the insufflations and deflations of a pressure cuff
Study: NCT06135025

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Telemonitoring
Description: the patients included receive a weekly phone call from the participating physician to to support self-management improvement, use of inhalation devices, rehabilitation, monitoring of signs/symptoms by treatment management, counseling, motivation, and prevention of exacerbations, early recognition of exacerbation signs and planify access to health care facility. at 1 month a Face to Face visit is planned to collect data.
Study: NCT05022628

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donafenib
Description: Donafenib treatment regimen.~1. Donafenib started on the day of the first radiation treatment.~2. starting dose 0.2 g bid twice daily orally on an empty stomach (1 hour before or 2 hours after a meal).~3. Surgery after at least 1 week off Donafinil; resume Donafinil dosing as soon as possible after postoperative wound healing until any of the following occurs, whichever occurs first: (i) the subject develops an intolerable toxic reaction that does not resolve after dose adjustment (see 5.3 for details); (ii) 12 months of postoperative dosing; (iii) the subject has the first imaging-confirmed recurrence of disease or withdraws from the study (whichever occurs first).~4. Dose adjustment/withdrawal: Subjects are allowed up to 2 dose adjustments if they experience an adverse event related to the trial drug during treatment.
Study: NCT05268354

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 6-week neuromuscular training program
Description: Training program consisting of three neuromuscular training sessions per week
Study: NCT05509010

Intervention type: PROCEDURE
Intervention: CTCA
Description: CTCA is performed as part of routine care procedure.

Intervention type: PROCEDURE
Intervention: CTCA
Description: CTCA is performed as part of routine care procedure.
Study: NCT06275737

Intervention type: OTHER
Group type: OTHER
Intervention: Prehabilitation program
Description: Cohort 1 - Prehabilitation program will be implemented during the last cycles of neoadjuvant chemotherapy (cycle 5 - cycle 6 or cycle 6 - cycle 8) and the weeks preceding surgery (planned 3-4 weeks after the last chemotherapy cycle)~Cohort 2 - Prehabilitation program will be implemented during the last cycles of neoadjuvant chemotherapy (cycle 2 - cycle 4) and the weeks preceding surgery (planned 3-4 weeks after the last chemotherapy cycle)
Study: NCT05588999

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cryotherapy Alone
Description: Patients in Group A were subjected to Cryotherapy Alone with liquid nitrogen and received maximum of four treatments given two to three weeks apart .~The liquid nitrogen was applied with a spray or a probe

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Cryotherapy plus Salicylic Acid
Description: Patients in Group B were subjected to cryotherapy plus with 50% salicylic acid to be properly applied for a maximum of eight weeks The liquid nitrogen was applied with a spray or a probe
Study: NCT05612464

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT05368922

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality rehabilitation
Description: The virtual reality rehabilitation protocol will be based on two perceptual-motor tasks (e.g., visuomotor tracking task and pointing task) in a 3D environment. The visuomotor tracking task will consist in tracking a virtual target moving with an effector manipulated by a remote controller. The pointing task will consist in tapping targets that are in a cube as quickly as possible with an effector manipulated by a remote controller. Both tasks will be performed in a 3D virtual playful environment.~The rehabilitation protocol will follow a progression through the manipulation of the virtual environment and the constraints of the tasks.
Study: NCT06051331

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: simulation-based breast health education
Description: The intervention group will receive simulation-based breast health education once a week for eight weeks. The simulation- based breast health education program will compose two part. The first part, it will theoretical education and second part will continue as practical education. On the plan date, a 60-min lecture will give about breast cancer, its risk factors, interventions to reduce the risk of breast cancer, the value of early diagnosis and cancer screening. After a 10-min break, course attendees watched a 20-min video, after which the course attendees' questions will answer.
Study: NCT05671419

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful Self-Compassion
Description: The course teaching mindfulness meditation skills relevant to cultivating self-compassion.
Study: NCT05892159

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HRV biofeedback
Description: An HRV biofeedback tool will be employed and utilized by individuals each day for the first 5 weeks during the intervention period.
Study: NCT05659641

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PerMed Stent Graft System In Surgical Operation
Description: PerMed Branch Stent Graft

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PerMed Stent Graft System In Surgical Operation
Description: PerMed Branch Stent Graft

Intervention type: DEVICE
Group type: OTHER
Intervention: Endovastec CRONUS® Intraoperative stent system
Description: CRONUS® Branch Stent Graft
Study: NCT06084624

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rebamipide mouthwash
Description: Rebamipide (REB), 2-(4-chlorobenzoylamino)-3-\[2(1H)-quinolinone-4-yl\]-propionic acid, is commonly used in cases of gastric ulcers, gastritis, and dry eye syndrome

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Betamethasone mouthwash
Description: Betamethasone is a potent glucocorticoid steroid. It is very soluble in water, and therefore it can be used as a mouthwash and has been used for symptomatic relief and treatment of recurrent aphthous ulcers
Study: NCT05024526

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: edaravone dexborneol or edaravone
Description: Edaravone dexborneol or edaravone is going to be used in two different groups to compare the efficacy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: edaravone dexborneol or edaravone
Description: Edaravone dexborneol or edaravone is going to be used in two different groups to compare the efficacy.
Study: NCT05854043

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified ERAS protocol
Description: Modified ERAS protocol for OLIF mainly include perioperative analgesic drug management, operation optimization in the anesthetic management, management of gastrointestinal function, and early mobilization management.~Perioperative analgesic usage:~Nonsteroidal anti-inflammatory drugs (NSAIDs) given when Visual Analogue Scale (VAS)\>3. Prehabilitation: Respiratory function exercise; walk at least 200 meters daily. Gastrointestinal function management: Oral lactulose use routinely. Sedation and analgesia: patient status index (PSI) 25-50; analgesia nociception index (ANI) 50-70. Local anesthetic: local infiltration around the psoas muscle. Postop off-bed activity: start mobilization within 24h.

Intervention type: OTHER
Group type: OTHER
Intervention: routine protocol
Description: Perioperative analgesic usage: NSAIDs given follow the patients requirement. Prehabilitation: None. Gastrointestinal function management: None. Sedation and analgesia: bispectral index (BIS) 40-60. Local anesthetic: None. Postop off-bed activity: mobilization follow the patients wish.
Study: NCT06426147

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-citrulline
Description: 1 or 2 sachets every 12 hours (200-300mg/kg/day depending on weight-band) for 28 days

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 or 2 sachets every 12 hours (depending on weight-band) for 28 days
Study: NCT06028217

Intervention type: OTHER
Intervention: prognosis status
Description: observatory; patients will be divided into survival group and mortality group according to their prognosis at day 28

Intervention type: OTHER
Intervention: prognosis status
Description: observatory; patients will be divided into survival group and mortality group according to their prognosis at day 28
Study: NCT05748678

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Compression pants
Description: Patients will have 3D photos taken each week of each buttock and thigh separately. A lymph scanner will also be used for each section to provide a percentage of water content. Weight will also be taken for each visit.~The first 2 weeks the patients will wear their regular pants, and from weeks 3-7 wear the compression pants provided. Weeks 8-9 the patients will be asked to resume to regular pants again
Study: NCT06454201

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: robotic natural orifice specimen extraction surgery
Description: After the rectum and its mesorectum were dissociated, the rectum was transected at 2 cm below the tumor by using a linear stapler. Then the rectal stump was incised and disinfected with iodophor, the protective sleeve was placed into the abdominal cavity through the assistant hole. An assistant delivered oval forceps into the pelvic cavity through the anus and used oval forceps to grip one end of the protective sleeve. Then slowly pulled out the protective sleeve. Eventually, one end of the protective sleeve was placed inside the abdominal cavity and the other outside the anus, completely covering the rectal stump and the perianal area. Tumor was pulled out of the rectal stump, then the colon was then disconnected at 10 cm above the tumor. The anvil was placed into the stump of the sigmoid colon and disinfected with iodophor, and then the anvil was delivered into the abdominal cavity. Place a circular stapler through the anus for end-to-end anastomosis of the rectum and sigmoid colon.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: robotic transabdominal specimen extraction surgery
Description: After the rectum and its mesorectum were dissociated, the rectum was transected at 2 cm below the tumor by using a linear stapler. Take a 6cm incision through the rectus abdominis muscle in the lower left abdomen and place an incision protective cover. Cut off the intestinal tube 10cm from the upper edge of the tumor and place a stapler base. The rectal stump was sutured with purse-string suture. Place a circular stapler through the anus for end-to-end anastomosis of the rectum and sigmoid colon. After completion of digestive tract reconstruction. The pelvic and abdominal cavities were washed repeatedly with normal saline until there were no blood remained. Close the abdominal cavity layer by layer.
Study: NCT05678647

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sucrosomial Iron
Description: 20 capsules of Sucrosomial Iron 30 mg is given after blood donation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iron Sulfate
Description: 20 tablets of oral iron sulphate (Duroferon®) 100 mg is given after blood donation
Study: NCT04105062

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LS301
Description: -LS301 is produced at the Optical Radiology Laboratory at Washington University School of Medicine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LS301
Description: -LS301 is produced at the Optical Radiology Laboratory at Washington University School of Medicine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LS301
Description: -LS301 is produced at the Optical Radiology Laboratory at Washington University School of Medicine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LS301
Description: -LS301 is produced at the Optical Radiology Laboratory at Washington University School of Medicine

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cancer Vision Goggles
Description: -Non-significant risk device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cancer Vision Goggles
Description: -Non-significant risk device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cancer Vision Goggles
Description: -Non-significant risk device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cancer Vision Goggles
Description: -Non-significant risk device
Study: NCT05244434

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Practice
Description: Given standard of care ribociclib + AI or palbociclib + AI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy of tumor tissue

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Undergo analysis of previously collected tumor tissue

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Undergo analysis of previously collected tumor tissue
Study: NCT04176081

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darolutamide
Description: Darolutamide will be administered orally as a tablet. Total daily dose is 1200 mg (2 tablets of 300 mg taken twice daily) for 6 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Description: Degarelix is administered by subcutaneous injection. The first dose of degarelix is 240 mg followed by monthly doses of 80 mg for a total treatment duration of 6 months.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation Therapy
Description: The total radiotherapy dose for all subjects will be: 36.25 Gy in 5Fx. The study will not include elective nodal irradiation. Every fraction will have 3D image guidance (i.e. cone-beam CT).

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: The total radiotherapy dose for all subjects will be: 36.25 Gy in 5Fx. The study will not include elective nodal irradiation. Every fraction will have 3D image guidance (i.e. cone-beam CT).
Study: NCT04172428

Intervention type: DIAGNOSTIC_TEST
Intervention: Functional MRI (fMRI)
Description: fMRI will be done on 3 separate MRI scanners to compare.
Study: NCT06404944

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: implantation
Description: 1. Incision the mucosa at the alveolar ridge, mucosal-periosteal flap elevation~2. Placement of the Astra Tech Implant EV Profile (Astra Tech Implant System®; Dentsply Sirona CIS, Sweden)~3. Placement healing abutment~4. Suturing the wound tightly

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: implantation
Description: 1. Incision the mucosa at the alveolar ridge, mucosal-periosteal flap elevation~2. Placement of the Astra Tech OsseoSpeed® TX dental implant (Astra Tech Implant System®; Dentsply Sirona CIS, Sweden)~3. Guided bone regeneration with xenogeneic bone material Bio-oss® (Geistlich Pharma AG, Sweden) and collagen membrane Bio-Gide® (Geistlich Pharma AG, Sweden)~4. Suturing the wound tightly
Study: NCT05948839

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: active rTMS treatment
Description: Participants will receive 3 sessions per day of 1800 pulses per session, lasting for 21 days. Individualized targets will be generated using the pBFS method.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham rTMS treatment
Description: The parameters in the sham arms are the same as the active stimulation groups. Stimulation was delivered by the same device as the active group fitted with a sham coil.
Study: NCT05588245

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Participants will undergo the same SDoH screener (AHC-Health Related Social Needs Tool) as full intervention participants, which will serve as the basis for a one-time brief session with the clinical research coordinator that will involve review of a 'Resource Guide' that provides a listing of available community resources to meet common social needs. Participants in this arm will also complete other prenatal and postpartum data collection items over the course of the study (with the exception of qualitative interviews).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community-based prenatal/perinatal/postpartum patient navigator
Description: Uses Freeman's principles of navigation to enhance patient access to care (e.g., help patients manage appointments), promote patient self-efficacy (e.g., connect patients to community housing, food, transportation resources), and sustain engagement with the healthcare system (e.g., bridge perinatal and primary care).